spacer
home > ict > spring 2020 > search and rescue
PUBLICATIONS
International Clinical Trials

Search and Rescue





ICT: How can companies identify if a clinical trial needs rescue?

Leslie Jones: It’s certainly a very big decision to make and no sponsor will take changing their CRO lightly. However, there naturally comes a point when missed timelines become critical. Continually failing to meet patient enrolment targets is a major red flag, but it’s important to also look at the reasons behind this. Could these problems have been foreseen or are they a result of poor planning on how and where to recruit patients, poor site selection, and/or poor patient involvement/ retention throughout the study?

Another common problem is vendors ‘lowballing’ their initial cost estimates to win the business, which leaves the CRO under resourced once the complexities of the trial become clear. It is not uncommon for CROs to dedicate less management energy and attention in cases where the sponsor is smaller or medium-sized, but, conversely, this may be the client that requires the most active oversight.

However, ultimately, the decision can come down to whether trust has been broken in the relationship between sponsor and CRO. When all members of the team agree it will be best to change the CRO, it is important to act on this decision and select a replacement with a rescue track record and experience.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Leslie Jones is the Executive Director of Clinical Operations US for WuXi Clinical. She has over 25 years of clinical research experience, ranging from working in a Phase I unit to performing GCP site audits and managing clinical and data teams on large-scale Phase II and Phase III trials. She has a great ability to unify internal and external resources and provides focus to the teams to achieve client goals and outcomes. She has been with WuXi Clinical for over a decade and is based in Austin, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera joins IPAC-RS as an Associate Member

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Nemera’s decision to join IPAC-RS is part of its commitment to advance science and innovation. Nemera is committed to enhancing better patient outcomes by seeking innovative solutions and contributing actively to discussions about the future of drug delivery devices. Its membership in IPAC-RS will facilitate this important commitment.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement